DETAILED ACTION
1. Claims 1-2, 10-13, 17-22, 27-28, 32-33, 35, 37-39 are pending in the instant application.
Applicant's election with traverse of group (I), claims 1-2, 10-13, 17-22, 27-28, 32-33 in the reply filed on 08/05/2026 is acknowledged.
The requirement is still deemed proper and is therefore made FINAL.
Examiner agree to rejoin groups (I-IV), claims 1-2, 10-13, 17-22, 27-28, 32-33. Claims 1-2, 10-13, 17-22, 27-28, 32-33 are examined. Claims 35, 37-39
are withdrawn per 37 CFR 1.142(b).
3. Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1-2, 10-13, 17-22, 27-28, 32-33 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Dineen et al., WO 2022271630. Dineen et al. discloses the instant claimed compound, which from the STN search is
PNG
media_image1.png
68
742
media_image1.png
Greyscale
PNG
media_image2.png
998
796
media_image2.png
Greyscale
PNG
media_image3.png
84
788
media_image3.png
Greyscale
PNG
media_image4.png
854
776
media_image4.png
Greyscale
PNG
media_image5.png
306
428
media_image5.png
Greyscale
, which anticipates the instant compounds. Therefore, the instant claims are anticipated by Dineen et al.
4. Claims 1-2, 10-13, 17-22, 27-28, 32-33 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Nagasaka et al., Journal of Thoracic Oncology (2021), 16(5), 740-763. Nagasaka et al. discloses the instant claimed compound, which from the STN search is
PNG
media_image6.png
82
756
media_image6.png
Greyscale
PNG
media_image7.png
358
478
media_image7.png
Greyscale
, which anticipates the instant compounds. Therefore, the instant claims are anticipated by Nagasaka et al.
5. Claims 1-2, 10-13, 17-22, 27-28, 32-33 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Meredith et al., Journal of Medicinal Chemistry (2022), 65(14), 9662-9677. Meredith et al. discloses the instant claimed compound, which from the STN search is
PNG
media_image8.png
92
792
media_image8.png
Greyscale
PNG
media_image9.png
258
436
media_image9.png
Greyscale
,
PNG
media_image10.png
332
814
media_image10.png
Greyscale
,
PNG
media_image11.png
328
784
media_image11.png
Greyscale
,
PNG
media_image12.png
712
772
media_image12.png
Greyscale
,
PNG
media_image13.png
328
780
media_image13.png
Greyscale
,
PNG
media_image14.png
724
822
media_image14.png
Greyscale
,
PNG
media_image15.png
336
788
media_image15.png
Greyscale
,
PNG
media_image16.png
726
854
media_image16.png
Greyscale
,
PNG
media_image17.png
338
794
media_image17.png
Greyscale
,
PNG
media_image18.png
328
790
media_image18.png
Greyscale
, which anticipates the instant compounds. Therefore, the instant claims are anticipated by Meredith et al.
6. Claims 1-2, 10-13, 17-22, 27-28, 32-33 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Brooijmans et al., WO 2022271612. Brooijmans et al. discloses the instant claimed compound, which from the STN search is
PNG
media_image19.png
64
754
media_image19.png
Greyscale
PNG
media_image20.png
618
760
media_image20.png
Greyscale
.
PNG
media_image21.png
270
494
media_image21.png
Greyscale
,
PNG
media_image22.png
318
780
media_image22.png
Greyscale
,
PNG
media_image23.png
316
806
media_image23.png
Greyscale
,
PNG
media_image24.png
336
764
media_image24.png
Greyscale
,
PNG
media_image25.png
636
806
media_image25.png
Greyscale
,
PNG
media_image26.png
696
840
media_image26.png
Greyscale
, which anticipates the instant compounds. Therefore, the instant claims are anticipated by Brooijmans et al.
7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is
571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor, can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/NILOOFAR RAHMANI/ Primary Examiner, Art Unit 1691
08/15/2026
Prosecution Insights